Determination of apatinib in tumor patients' plasma by liquid chromatography tandem mass spectrometry and its application

doi:10.12092/j.issn.1009-2501.2018.07.011

Abstract

Abstract:

AIM: To establish a rapid, accurate liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the determination of apatinib in tumor patients and apply this method to analyze the clinical samples. METHODS: Sorafenib was employed as the internal standard. The analyte and internal standard were extracted from plasma by protein precipitation with acetonitrile and separated on Eclipse Plus C18 column (2.1 mm×100 mm, 3.5 μm) , mobile phase consisted of acetonitrile-10 mmol/L ammonium acetate (85∶15, V/V, containing 0.1% formic acid) at the flow rate of 0.25 mL/min. Electrospray ionization (ESI) source was applied and operated in the positive multiple reaction monitoring (MRM) mode.The MS/MS ion transitions monitored were m/z 398.1→m/z 212.0 and m/z 465.3→m/z 270.1 for apatinib and internal standard, respectively. After methodology validation, this method was applied for the clinical analysis of apatinib in plasma from tumor patients.RESULTS:Chromatograms showed no endogenous interfering peaks with blank samples. The standard curves were demonstrated to be liner in the range of 2.0-2 000 μg/L (r=0.996 8). The RSD of inter-day (n=5) and intra-day (n=3) for four different concentration levels were less than 15%, The average recoveries were between 78.0% and 87.8%.The internal standard normalized matrix effect 92.4% and 107.3%. CONCLUSION: The method is specific, sensitive and suitable for clinical determination of apatinib in tumor patients plasma efficiently.

Key words: apatinib, LC-MS/MS, plasma concentration, pharmacokinetics

CLC Number:

R917
R969.1

LI Li, LI He, LIU Xing'e, WEI Nan. Determination of apatinib in tumor patients' plasma by liquid chromatography tandem mass spectrometry and its application[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(7): 790-795.

References

［1］Zhang H. Apatinib for molecular targeted therapy in tumor［J］. Drug Des Devel Ther, 2015, 9(11):6075-6081.

［2］Qin SK, Li J. Experts consensus on the clinical application of apatinib in gastric cancer treatment［J］. Chin Clin Oncol, 2015, 20(9):841-847.

［3］鲁丁瑜,李娜,李志平.多靶点抗肿瘤新药阿帕替尼的研究进展［J］.华西药学杂志,2017,32(1):104-108.

［4］朱丹,赵宏伟,赵健琦,等.肿瘤分子靶向药物阿帕替尼的临床研究进展［J］.中国医院药学杂志,2017,37(2):194-198.

［5］陈淑慧,阳帆帆,何君,等.胃癌靶向治疗研究最新进展［J］.中国临床药理学与治疗学,2015,20(8):950-955.

［6］武健,尹芳,罗贯虹,等.经肝动脉化疗栓塞术联合阿帕替尼治疗中晚期原发性肝癌的效果及安全性分析［J］.临床肝胆病杂志,2018(4):775-778.

［7］宋锦添,陈奕贵,许春伟,等.阿帕替尼治疗53例晚期原发性肝癌的疗效［J］.临床与病理杂志,2017,37(3):557-563.

［8］刘凯,毋永娟.靶向药物阿帕替尼三线治疗晚期乳腺癌单臂、单中心Ⅱ期临床研究［J］.医学理论与实践,2017,30(3):320-322.

［9］Ding J, Chen X, Dai X, et al. Simultaneous determination of apatinib and its four major metabolites in human plasma using liquid chroma- tography- tandem mass spectrometry and its application to a pharmacokineticstudy［J］. J Chromatogr B,2012, 895(7):108-115.

［10］Zhou Y, Wang S, Ding T, et al. Evaluation of the effect of apatinib (YN968D1) on cytochrome P450 enzymes with cocktail probe drugs in rats by UPLC-MS/MS［J］. J Chromatogr B, 2014, 973: 68-75.

［11］南峰, 徐楠, 陈枳潓,等.快速灵敏的LC-MS/MS法测定人血浆中阿莫西林并应用于两种制剂的一致性评价［J］.中国临床药理学与治疗学,2018,23(1):73-77.

［12］李力,李贺,黄越,等.LC-MS/MS同时测定大鼠血浆中5种银杏酸浓度及其药动学研究［J］.中国现代应用药学,2017,34(12):1658-1662.

［13］Widmer N,Bardin C,Chatelut E,et al. Review of therapeutic drug monitoring of anticancer drugs part two-targeted therapies［J］. Eur J Cancer,2014,50: 2020 -2036.

［14］Mai H, Huang J, Zhang Y, et al. In-vivo relation between plasma concentration of sorafenib and its safety in Chinese patients with metastatic renal cell carcinoma: a single-center clinical study［J］. Oncotarget, 2017, 8(26): 43458.

［15］Fukudo M,Ito T,Mizuno T,et al. Exposure - toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepatocellular carcinoma［J］.Clin Pharmacokinet,2014, 53: 185-196.

［16］Tandia M, Mhiri A, Paule B, et al. Correlation between clinical response to sorafenib in hepatocellular carcinoma treatment and polymorphisms of P-glycoprotein (ABCB1) and of breast cancer resistance protein (ABCG2): monocentric study［J］. Cancer Chemoth Pharm, 2017, 79(4): 759-766.

［17］Widmer N,Bardin C,Chatelut E,et al. Review of therapeutic drug monitoring of anticancer drugs part two -targeted therapies［J］. Eur J Cancer,2014,50: 2020-2036.

［18］Fukudo M,Ito T,Mizuno T,et al. Exposure- toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepatocellular carcinoma［J］.Clin Pharmacokinet,2014, 53: 185 -196.

［19］时佳琪,刘超,张艳桥,等.甲磺酸阿帕替尼治疗恶性肿瘤的临床不良反应分析［J］.中国肿瘤临床,2018,45(4):191-195.

[1]	WU Yujie, ZHAO Chengcheng, XI Qing. Evaluation of tegacycline regimens in treatment of gram-negative bacterial infections with Monte Carlo simulation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1027-1033.
[2]	LI Kun, LI Lulu, LI Nannan, HU Weihong, ZHOU Jianchao. Effects of glycaemic control and CYP3A5 polymorphisms on tacrolimus trough concentrations after adult kidney transplantation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 767-774.
[3]	HE Xueru, LI Ying, MA Yinling, FU Yuhao, XUN Xuejiao, DONG Zhanjun. Pharmacokinetic interaction study between sorafenib and dapagliflozin in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 498-507.
[4]	HUANG Zhiwei, LI Yi, XU Xiaoyong, ZHANG Lei, SHEN Yifeng, LI Huafang. Comparison of calculation results of five population pharmacokinetic analysis tools [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 525-535.
[5]	LI Mengxue, HE Jie, YU Xiaxia, HU Linlin, SHAO Hua. Research progress in population pharmacokinetics of rituximab [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 468-474.
[6]	YAN Qiangyong, XIANG Daxiong, ZHU Ronghua, YANG Lingfeng, YANG Xiding, LI Jingjing, FAN Xiao, LIU Sai, XIONG Shoujun, FANG Pingfei. Bioequivalence study of cinacalcet hydrochloride tablets in healthy Chinese volunteers [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 171-177.
[7]	LIU Lu, SHI Yufei, HE Qingfeng, XU Fengyan, WANG Kun, CAI Weimin, XIANG Xiaoqiang. Application of population modeling analysis to evaluate the impact of gene polymorphism on drug PK/PD [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1275-1282.
[8]	ZHOU Jiating, ZHANG Xuan, XIE Zilan, LI Zhi. Interactions and clinical significance of gut microbiota and levothyroxine [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1307-1314.
[9]	LI Xuejing, JIANG Jinping, LI Sining, WAN Linfei, ZHOU Xiangxiang, YANG Lian, LAN Ke. A bioequivalence study of generic and brand clozapine in schizophrenic patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1121-1130.
[10]	WU Lili, LIANG Zhi, HUANG Siyong, WANG Yan. Effect of augmented renal clearance (ARC) on the pharmacokinetics, efficacy, and safety of vancomycin in patients with infective endocarditis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1139-1145.
[11]	MA Shen, LIU Yushuo, TANG Hui, CHEN Wenbin, GAO Ling. Pharmacokinetics and clinical significance of drugs for improving nonalcoholic fatty liver disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 908-918.
[12]	DAI Jingyi, WANG Jingjing, ZHANG Jing, YU Jicheng, LI Nanyang, HUANG Zhiwei. Clinical application and research progress of inhaled methoxyflurane [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 808-813.
[13]	PAN Shu, WU Yijin, ZHANG Sasa, WANG Qihai, LUO Tingting, YIN Qin. Pharmacokinetics of methotrexate mediated by organic anion transporter 3 in adjuvant induced arthritis rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(5): 516-525.
[14]	WU Juan, WANG Zhiqiang, ZHOU Renpeng, YANG Jingjing, QIN Huiling, ZHANG Qian, LU Chao, HU Wei. Bioequivalence trial of fasting oral sorafenib tosylate tablets in healthy Chinese subjects [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 281-286.
[15]	ZHANG Jinhua, LIU Maobai, CAI Mingzhi, ZHENG Yingli, LAO Haiyan, XIANG Qian, DU Liping, ZHU Zhu, DONG Jing, ZUO Xiaocong, LI Xingang, SHANG Dewei, CHEN Bing, YE Yanrong, WANG Yuzhu, GAO Jianjun, ZHANG Jian, CHEN Wansheng, XIE Haitang, JIAO Zheng. Model informed precision dosing of warfarin: China expert consensus report (2022 version) [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1201-1212.